Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

Open Access 01-12-2020 | Leishmania | Research article

Using Q-methodology to understand the perspectives and practical experiences of dermatologists about treatment difficulties of cutaneous leishmaniasis

Authors: Dindar S. Qurtas, Nazar Pauls Shabila

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

During the outbreak of cutaneous leishmaniasis in the Kurdistan Region of Iraq that started in 2015, the course of the disease and the treatment were not consistent with the available literature. Physicians, particularly dermatologists, faced challenges with treating the cutaneous leishmaniasis lesions with high rates of treatment failure and resistance to treatment. We used Q-methodology to understand the range and diversities of opinions and the practical experiences of dermatologists about the treatment difficulties of cutaneous leishmaniasis.

Methods

This Q-methodology study was carried out in Erbil, Kurdistan Region of Iraq, and involved 37 dermatologists. A set of 40 statements related to different aspects of difficulties and uncertainties of treating cutaneous leishmaniasis was prepared. The dermatologists were requested to distribute the 40 statements into a scaled grid of nine piles from least agree to most agree. We applied by-person factor analysis using PQMethod 2.35 for the data analysis.

Results

The analysis revealed two different viewpoints about the treatment of cutaneous leishmaniasis and a consensus viewpoint. The first viewpoint emphasized the use of sodium stibogluconate-based combination therapy, concerns with treatment failure, and lack of compliance with the treatment. The second viewpoint emphasized the lack of standard treatment and advances in the treatment of cutaneous leishmaniasis. There was a consensus between both groups of respondents about many aspects of the treatment of cutaneous leishmaniasis, including considering sodium stibogluconate the first drug of choice for cutaneous leishmaniasis treatment.

Conclusions

This study revealed a diversity of viewpoints and uncertainties about the effectiveness of the available treatment modalities and treatment difficulties and failure. Interrupted supply and poor quality of the available drugs and lack of a standard and advanced treatment are the main problems facing the treatment of cutaneous leishmaniasis. More research is required to determine the best treatment modalities for the different types of cutaneous leishmaniasis. There is a need for the development of treatment guidelines specific to the Iraqi context with a particular focus on the treatment of the resistant and atypical cases of cutaneous leishmaniasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014;107:7–14.PubMed McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. QJM. 2014;107:7–14.PubMed
2.
go back to reference World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010;xii-xiii(949):1–186. World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2010;xii-xiii(949):1–186.
3.
go back to reference Alvar J, ID V é, Bern C. Leishmaniasis worldwide and global estimates of Its Incidence. PLoS One. 2012;7:35671. Alvar J, ID V é, Bern C. Leishmaniasis worldwide and global estimates of Its Incidence. PLoS One. 2012;7:35671.
4.
go back to reference World Health Organization. Country Cooperation Strategy for WHO and Iraq, 2012-2017. In: World Health Organization, regional Office for the Eastern Mediterranean, WHO, vol; 2013. World Health Organization. Country Cooperation Strategy for WHO and Iraq, 2012-2017. In: World Health Organization, regional Office for the Eastern Mediterranean, WHO, vol; 2013.
5.
go back to reference Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infec Ther. 2003;1(4):563–70. Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infec Ther. 2003;1(4):563–70.
6.
go back to reference Abdulla QB, Shabila NP, Al-Hadithi TS. An outbreak of cutaneous leishmaniasis in Erbil governorate of Iraqi Kurdistan region in 2015. J Infect Dev Ctries. 2018;12(8):600–7.PubMed Abdulla QB, Shabila NP, Al-Hadithi TS. An outbreak of cutaneous leishmaniasis in Erbil governorate of Iraqi Kurdistan region in 2015. J Infect Dev Ctries. 2018;12(8):600–7.PubMed
7.
go back to reference Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. London: Elsevier Limited; 2012. p. 1360–78. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. London: Elsevier Limited; 2012. p. 1360–78.
8.
go back to reference Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE, Strausbaugh LJ. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004;39(11):1674–80.PubMed Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE, Strausbaugh LJ. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis. 2004;39(11):1674–80.PubMed
9.
go back to reference Qurtas DS. Cutaneous Leishmaniasis in Erbil governorate: clinical manifestations and disease course. Med J Islam Repub Iran. 2018;32:71.PubMedPubMedCentral Qurtas DS. Cutaneous Leishmaniasis in Erbil governorate: clinical manifestations and disease course. Med J Islam Repub Iran. 2018;32:71.PubMedPubMedCentral
10.
go back to reference Mirahmadi H, Rezaee N, Mehravaran A, Heydarian P, Raeghi S. Detection of species and molecular typing of Leishmania in suspected patients by targeting cytochrome b gene in Zahedan, southeast of Iran. Vet World. 2018;11(5):700–5.PubMedPubMedCentral Mirahmadi H, Rezaee N, Mehravaran A, Heydarian P, Raeghi S. Detection of species and molecular typing of Leishmania in suspected patients by targeting cytochrome b gene in Zahedan, southeast of Iran. Vet World. 2018;11(5):700–5.PubMedPubMedCentral
11.
go back to reference de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol. 2015;16(2):99–109.PubMedPubMedCentral de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol. 2015;16(2):99–109.PubMedPubMedCentral
12.
go back to reference Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep. 2013;(2):31–41. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep. 2013;(2):31–41.
13.
go back to reference Monge-Maillo B, López-Vélez R. Therapeutic options for Old World cutaneous Leishmaniasis and New World cutaneous and Mucocutaneous Leishmaniasis. Drugs. 2013;73(17):1889–920.PubMed Monge-Maillo B, López-Vélez R. Therapeutic options for Old World cutaneous Leishmaniasis and New World cutaneous and Mucocutaneous Leishmaniasis. Drugs. 2013;73(17):1889–920.PubMed
15.
go back to reference Gonzalez U. Cochrane reviews on neglected diseases: the case of cutaneous leishmaniasis. Cochrane Database Syst Rev. 2013;3:ED000055. Gonzalez U. Cochrane reviews on neglected diseases: the case of cutaneous leishmaniasis. Cochrane Database Syst Rev. 2013;3:ED000055.
16.
go back to reference Qurtas DS. Effect of azithromycin in treatment of cutaneous leishmaniasis. Med J Basrah Univ. 2018;36(2):97–102. Qurtas DS. Effect of azithromycin in treatment of cutaneous leishmaniasis. Med J Basrah Univ. 2018;36(2):97–102.
17.
go back to reference Bahnan BA, Shabu SA, Sleman SA. Intralesional pentostam versus intralesional metronidazole in treating cutaneous leishmaniasis: a comparison study. Zanco J Med Sci. 2019;23(2):266–72. Bahnan BA, Shabu SA, Sleman SA. Intralesional pentostam versus intralesional metronidazole in treating cutaneous leishmaniasis: a comparison study. Zanco J Med Sci. 2019;23(2):266–72.
18.
go back to reference Tamiru HF, Mashalla YJ, Mohammed R, Tshweneagae GT. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia. BMC Infect Dis. 2019;1:855. Tamiru HF, Mashalla YJ, Mohammed R, Tshweneagae GT. Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia. BMC Infect Dis. 2019;1:855.
20.
go back to reference Shinebourne P, Adams M. Q-methodology as a phenomenological research method. Existent Anal. 2007;18(1):103–16. Shinebourne P, Adams M. Q-methodology as a phenomenological research method. Existent Anal. 2007;18(1):103–16.
21.
go back to reference Smith NW. Current systems in psychology: history, theory, research, and applications. Belmont: Wadsworth; 2001. Smith NW. Current systems in psychology: history, theory, research, and applications. Belmont: Wadsworth; 2001.
22.
go back to reference Perz J, Ussher JM, Gilbert E. Constructions of sex and intimacy after cancer: Q methodology study of people with cancer, their partners, and health professionals. BMC Cancer. 2013;13:270.PubMedPubMedCentral Perz J, Ussher JM, Gilbert E. Constructions of sex and intimacy after cancer: Q methodology study of people with cancer, their partners, and health professionals. BMC Cancer. 2013;13:270.PubMedPubMedCentral
23.
go back to reference Watts S, Stenner P. Doing Q methodological research: theory, method and interpretation. London: SAGE Publications Ltd; 2012. Watts S, Stenner P. Doing Q methodological research: theory, method and interpretation. London: SAGE Publications Ltd; 2012.
25.
go back to reference Brown SR. Political subjectivity: applications of Q methodology in political science. New Haven: Yale University Press; 1980. Brown SR. Political subjectivity: applications of Q methodology in political science. New Haven: Yale University Press; 1980.
26.
go back to reference Shinebourne P. Using Q method in qualitative research. IJQM. 2009;8(1):93–7. Shinebourne P. Using Q method in qualitative research. IJQM. 2009;8(1):93–7.
27.
go back to reference Stainton RR. In: Smith JA, Harre R, Van Langenhove L, editors. Q methodology. In Rethinking methods in psychology. Thousand Oaks: Sage; 1995. p. 178–92. Stainton RR. In: Smith JA, Harre R, Van Langenhove L, editors. Q methodology. In Rethinking methods in psychology. Thousand Oaks: Sage; 1995. p. 178–92.
28.
go back to reference Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5(11):873–82.PubMed Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5(11):873–82.PubMed
29.
go back to reference van Griensven J, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet. 2011;377:443–4.PubMed van Griensven J, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet. 2011;377:443–4.PubMed
30.
go back to reference Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol. 2001;26(1):21–6.PubMed Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol. 2001;26(1):21–6.PubMed
31.
go back to reference Bafghi AF, Noorbala M, Noorbala MT, Aghabagheri M. Anti Leishmanial effect of zinc sulphate on the viability of Leishmania tropica and L. major promastigotes. Jundishapur J Microbiol. 2014;7(9):e11192. Bafghi AF, Noorbala M, Noorbala MT, Aghabagheri M. Anti Leishmanial effect of zinc sulphate on the viability of Leishmania tropica and L. major promastigotes. Jundishapur J Microbiol. 2014;7(9):e11192.
32.
33.
go back to reference Passero LF, Cruz LA, Santos-Gomes G, Rodrigues E, Laurenti MD, Lago JH. Conventional versus natural alternative treatments for leishmaniasis: a review. Curr Top Med Chem. 2018;18(15):1275–86.PubMed Passero LF, Cruz LA, Santos-Gomes G, Rodrigues E, Laurenti MD, Lago JH. Conventional versus natural alternative treatments for leishmaniasis: a review. Curr Top Med Chem. 2018;18(15):1275–86.PubMed
34.
go back to reference Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg. 2009;80(2):172–5.PubMed Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg. 2009;80(2):172–5.PubMed
35.
go back to reference Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini HA. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003;97(5):493–8.PubMed Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini HA. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003;97(5):493–8.PubMed
36.
go back to reference Gurei MS, Tatli N, Ozbilge H, Erel O, Seyrek A, Kocyigit A, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30(1):169–76.PubMed Gurei MS, Tatli N, Ozbilge H, Erel O, Seyrek A, Kocyigit A, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30(1):169–76.PubMed
37.
go back to reference Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol. 1986;25(7):473–5.PubMed Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol. 1986;25(7):473–5.PubMed
38.
go back to reference David JR. The successful use of radiofrequency-induced heat therapy for cutaneous leishmaniasis: a review. Parasitology. 2018;145(4):527–36.PubMed David JR. The successful use of radiofrequency-induced heat therapy for cutaneous leishmaniasis: a review. Parasitology. 2018;145(4):527–36.PubMed
39.
go back to reference Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis. 1998;27(6):1457–64.PubMed Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis. 1998;27(6):1457–64.PubMed
40.
go back to reference Elmekki MA, Elhassan MM, Ozbak HA, Qattan IT, Saleh SM, Alharbi AH. Epidemiological trends of cutaneous leishmaniasis in Al-Madinah Al-Munawarah province, western region of Saudi Arabia. J Global Infect Dis. 2017;9(4):146–50. Elmekki MA, Elhassan MM, Ozbak HA, Qattan IT, Saleh SM, Alharbi AH. Epidemiological trends of cutaneous leishmaniasis in Al-Madinah Al-Munawarah province, western region of Saudi Arabia. J Global Infect Dis. 2017;9(4):146–50.
41.
go back to reference Sharquie KE. A new intralesional therapy of cutaneous leishmaniasis with hypertonic sodium chloride solution. J Dermatol. 1995;22(10):732–7.PubMed Sharquie KE. A new intralesional therapy of cutaneous leishmaniasis with hypertonic sodium chloride solution. J Dermatol. 1995;22(10):732–7.PubMed
42.
go back to reference Al Hamdi KI, Awad AH, Moker HM. Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. East Mediterr Health J. 2010;16(1):89–93.PubMed Al Hamdi KI, Awad AH, Moker HM. Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. East Mediterr Health J. 2010;16(1):89–93.PubMed
43.
go back to reference Khosravi A, Sharifi I, Fekri A, Kermanizadeh A, Bamorovat M, Mostafavi M, et al. Clinical features of anthroponotic cutaneous leishmaniasis in a major focus, southeastern Iran, 1994-2014. Iran J Parasitol. 2017;12(4):544–53.PubMedPubMedCentral Khosravi A, Sharifi I, Fekri A, Kermanizadeh A, Bamorovat M, Mostafavi M, et al. Clinical features of anthroponotic cutaneous leishmaniasis in a major focus, southeastern Iran, 1994-2014. Iran J Parasitol. 2017;12(4):544–53.PubMedPubMedCentral
44.
go back to reference Brown SR. Q methodology as the foundation for a science of subjectivity. Operant Subjectivity. 1995;18(1/2):1–16. Brown SR. Q methodology as the foundation for a science of subjectivity. Operant Subjectivity. 1995;18(1/2):1–16.
45.
go back to reference Amin Z. Q methodology–a journey into the subjectivity of human mind. Singap Med J. 2000;41(8):410–4. Amin Z. Q methodology–a journey into the subjectivity of human mind. Singap Med J. 2000;41(8):410–4.
46.
go back to reference Mary C, Faraut F, Deniau M, Dereure J, Aoun K, Ranque S, et al. Frequency of drug resistance gene amplification in clinical Leishmania strains. Int J Microbiol. 2010;2010:819060.PubMedPubMedCentral Mary C, Faraut F, Deniau M, Dereure J, Aoun K, Ranque S, et al. Frequency of drug resistance gene amplification in clinical Leishmania strains. Int J Microbiol. 2010;2010:819060.PubMedPubMedCentral
Metadata
Title
Using Q-methodology to understand the perspectives and practical experiences of dermatologists about treatment difficulties of cutaneous leishmaniasis
Authors
Dindar S. Qurtas
Nazar Pauls Shabila
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05365-0

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.